Instrument Inactif

Communiqués Asarina Pharma AB

Actions

ASAP

SE0011641794

Recherche biotechnologique et médicale

Communiqués

07/02/25	Asarina Pharma sells Sepranolone assets to Relmada Therapeutics	AQ
16/09/24	Asarina Pharma AB (publ) shares to be delisted and the last day of trading is 1 October 2024	AQ
13/09/24	Asarina Pharma applies for the delisting of the company's shares	AQ
21/08/24	Bulletin from the extraordinary general meeting and first control meeting in Asarina Pharma	AQ
22/07/24	NOTICE OF EXTRAORDINARY GENERAL MEETING AND FIRST CONTROL MEETING IN ASARINA PHARMA AB (PUBL)	AQ
18/07/24	ASARINA PHARMA ANNOUNCES OUTCOME OF PARTNERING PROCESS, CONTROL BALANCE SHEET AND PROPOSAL TO LIQUIDATE	AQ
27/06/24	Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)	AQ
05/06/24	ASARINA PHARMA AB RELEASES ANNUAL REPORT 2023	AQ
04/06/24	ASARINA PHARMA AB (PUBL) RELEASES ANNUAL REPORT 2023	AQ
28/05/24	Asarina Pharma AB announces new date for the release of Annual Report for 2023	AQ
21/05/24	Asarina Pharma AB announces new date for the release of Annual Report for 2023	AQ
27/02/24	ASARINA PHARMA AB (PUBL) RELEASES YEAR-END REPORT 2023	AQ
30/11/23	Asarina Pharma AB changes Certified Adviser to Carnegie Investment Bank AB	AQ
16/11/23	Asarina Pharma updates on partnering and financials	AQ
23/08/23	Asarina Pharma AB (publ) releases First Half-Year Report (H1/2023)	AQ
24/05/23	ASARINA PHARMA - POSITIVE TOURETTE SYNDROME RESULTS TO BE PRESENTED AT ESSTS, 15TH EUROPEAN CONFERENCE ON TOURETTE SYNDROME AND TIC DISORDERS	AQ
22/05/23	Bulletin from the Annual General Meeting of Asarina Pharma AB (publ)	AQ
08/05/23	Asarina Pharma's positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America	AQ
05/05/23	Asarina Pharma's positive Phase IIa Tourette Syndrome results to be presented at TicCon, the Virtual National Conference of the Tourette Association of America	AQ
01/05/23	Asarina Pharma AB (publ) releases Annual Report 2022	AQ
28/04/23	Asarina Pharma AB (publ) releases Annual Report 2022	AQ
18/04/23	NOTICE OF ANNUAL GENERAL MEETING IN ASARINA PHARMA AB (PUBL)	AQ
03/04/23	Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette syndrome	AQ
01/04/23	Asarina Pharma publishes positive results from its Phase IIa study of Sepranolone in Tourette Syndrome	AQ
27/02/23	Asarina Pharma AB (publ) releases Year-End Report 2022	AQ